Literature DB >> 18856032

[Influenza season 2007/'08 in the Netherlands: antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season].

G F Rimmelzwaan1, J C de Jong, G A Donker, A Meijer, R A M Fouchier, A D M E Osterhaus.   

Abstract

The first signs of influenza activity during the 2007/'08 influenza season in the Netherlands were sporadic isolations of influenza viruses between week 40 and week 52 of 2007. The frequency of virus isolations and clinical influenza activity increased after week 1 of 2008 and peaked around week 9. In this week, 7.2 patients with influenza-like illness were recorded per 10,000 inhabitants. The influenza epidemic was caused primarily by influenza A/H1N1 viruses and influenza B viruses. Two antigenically distinct variants of influenza A/H1N1 viruses were isolated, which resembled the 2007/'08 vaccine reference strain A/Solomon Islands/3/06 and the new vaccine reference strain A/Brisbane/59/07, respectively. The most remarkable finding was that 27% of the A/H1N1 viruses isolated in the Netherlands during the 2007/'08 epidemic were resistant to the neuraminidase inhibitor oseltamivir. The isolated influenza B viruses originated from the B/Yamagata/16/88 lineage and did not match the vaccine strain, which originated from a different and antigenically distinct lineage of influenza B viruses (B/Victoria/2/87). Only a small number of influenza A/H3N2 viruses was isolated, which were related to the vaccine strain for this subtype (A/Wisconsin/67/05). Thus in contrast to previous influenza seasons, A/H3N2 viruses did not play a major role in the 2007/'08 influenza season in the Netherlands. For the 2008/'09 influenza season, the World Health Organization has recommended the following vaccine composition: A/Brisbane/59/07 (H1N1), A/Brisbane/10/07 (H3N2) and B/Florida/4/06.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18856032

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  6 in total

1.  Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands.

Authors:  R Bodewes; G de Mutsert; F R M van der Klis; M Ventresca; S Wilks; D J Smith; M Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

2.  Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008.

Authors:  Frederika Dijkstra; Marcel Jonges; Ruud van Beek; Gé A Donker; François G Schellevis; Marion Koopmans; Marianne A B van der Sande; Albert D M E Osterhaus; Charles A B Boucher; Guus F Rimmelzwaan; Adam Meijer
Journal:  Open Virol J       Date:  2011-12-23

3.  Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes.

Authors:  Maryam Darvishian; Frederika Dijkstra; Eva van Doorn; Maarten J Bijlsma; Gé A Donker; Marit M A de Lange; Laura M Cadenau; Eelko Hak; Adam Meijer
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

4.  Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups.

Authors:  Eva van Doorn; Maryam Darvishian; Frederika Dijkstra; Gé A Donker; Pieter Overduin; Adam Meijer; Eelko Hak
Journal:  Vaccine       Date:  2017-04-12       Impact factor: 3.641

5.  Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers.

Authors:  Josefina García; Merly Sovero; Alberto L Torres; Jorge Gomez; Richard Douce; Melvin Barrantes; Felix Sanchez; Mirna Jimenez; Guillermo Comach; Ivette de Rivera; Roberto Agudo; Tadeusz Kochel
Journal:  Influenza Other Respir Viruses       Date:  2009-03       Impact factor: 4.380

6.  Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections.

Authors:  Liselotte van Asten; Paul Bijkerk; Ewout Fanoy; Annemarijn van Ginkel; Anita Suijkerbuijk; Wim van der Hoek; Adam Meijer; Harry Vennema
Journal:  Influenza Other Respir Viruses       Date:  2016-01       Impact factor: 4.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.